List of articles with "Ulcerative Colitis"

Omvoh FDA Approval

Omvoh FDA Approval

United States Indianapolis Ulcerative Colitis Eli Lilly Omvoh
Promising Icotrokinra Results

Promising Icotrokinra Results

United States Ulcerative Colitis Johnson & Johnson Phoenix Icotrokinra
Omvoh and Bowel Urgency

Omvoh and Bowel Urgency

USA Indianapolis Ulcerative Colitis Omvoh Lilly
Cristcot's UC Innovation

Cristcot's UC Innovation

USA Austin Ulcerative Colitis Cristcot HCA Therapy
Loopback Wins Award

Loopback Wins Award

USA Dallas Ulcerative Colitis Loopback Analytics NASP Annual Meeting
Icotrokinra Treatment

Icotrokinra Treatment

United States Ulcerative Colitis Johnson & Johnson Spring House Icotrokinra
TREMFYA® Breakthrough

TREMFYA® Breakthrough

USA Ulcerative Colitis TREMFYA® Spring House guselkumab
Omvoh: Four-Year Efficacy

Omvoh: Four-Year Efficacy

United States Indianapolis Ulcerative Colitis Eli Lilly Omvoh
TREMFYA® Approved!

TREMFYA® Approved!

United States Ulcerative Colitis TREMFYA Horsham guselkumab
Inflammatory Bowel Diseases Surge

Inflammatory Bowel Diseases Surge

Japan Ulcerative Colitis Tokyo Crohn's Disease Japan Research
Cristcot at GI ReConnect

Cristcot at GI ReConnect

USA Ulcerative Colitis Cristcot GI ReConnect Aurora, Colorado
Cristcot's New CCO

Cristcot's New CCO

USA Ulcerative Colitis Concord Cristcot Richard Kim
Tremfya® Released

Tremfya® Released

Japan Ulcerative Colitis TREMFYA® Johnson & Johnson Tokyo
Tremfya® Long-Term Results

Tremfya® Long-Term Results

USA San Diego Ulcerative Colitis Johnson & Johnson TREMFYA
TREMFYA® Outperforms in UC

TREMFYA® Outperforms in UC

United States San Diego Ulcerative Colitis Johnson & Johnson TREMFYA
TREMFYA® and UC Treatment

TREMFYA® and UC Treatment

United States San Diego Ulcerative Colitis TREMFYA® guselkumab
Rise Therapeutics

Rise Therapeutics

USA San Diego Ulcerative Colitis Rise Therapeutics R-3750
Ulcerative Colitis Breakthrough

Ulcerative Colitis Breakthrough

United States Ulcerative Colitis Palatin Technologies PL8177 Cranbury
Hope for Ulcerative Colitis

Hope for Ulcerative Colitis

Taiwan Taipei Ulcerative Colitis MS-20 Microbio
Icotrokinra's Promising Results

Icotrokinra's Promising Results

United States Ulcerative Colitis Johnson & Johnson Spring House Icotrokinra
Adiso's ADS051 Phase 1 Results

Adiso's ADS051 Phase 1 Results

United States Ulcerative Colitis Concord Adiso Therapeutics ADS051
TREMFYA® Induction Options

TREMFYA® Induction Options

USA Ulcerative Colitis Spring House TREMFYA guselkumab
Orismilast Data at ECCO

Orismilast Data at ECCO

Ulcerative Colitis Denmark Hellerup Orismilast UNION therapeutics
AC-101 Phase Ib Trial

AC-101 Phase Ib Trial

USA New York Ulcerative Colitis Accropeutics AC-101
IBD: Key Insights

IBD: Key Insights

United States Ulcerative Colitis Crohn's Disease Mission IBD
PL8177 Trial Update

PL8177 Trial Update

USA Ulcerative Colitis Palatin Technologies PL8177 Cranbury
TREMFYA® FDA Approval

TREMFYA® FDA Approval

United States Ulcerative Colitis TREMFYA® Johnson & Johnson Spring House

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.